Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II lapatinib in relapsed or refractory inflammatory breast cancer
2004-001906-29Phase 2Completed
- Sponsor
- GSK
- Start
- Jun 2005
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of lapatinib in inflammatory breast cancer (IBC), sponsored by GSK. Primary endpoint: Objective Response Rate. Started Jun 2005; status: completed.
02
Drugs
lapatinib
03
Conditions
inflammatory breast cancer (IBC)
Beyond the preview
Go deeper on 2004-001906-29.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2004-001906-29.